Evidence map›Paper›PMID 42792228›Full record

ReviewAntioxidants (Basel, Switzerland)2026

Molecular Drivers of Cognitive Decline and Neuroprotection in Obstructive Sleep Apnea: A Narrative Review.

Julia Jaromirska, Piotr Białasiewicz, Dominik Strzelecki, Agata Gabryelska

Abstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Julia JaromirskaDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0009-0004-6474-5922
Piotr BiałasiewiczDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 92-215 Lodz, Poland.
Dominik StrzeleckiDepartment of Affective and Psychotic Disorders, Medical University of Lodz, 92-216 Lodz, Poland.ORCID 0000-0002-8559-1078
Agata GabryelskaDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0002-4430-6488

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obstructive sleep apnea is a common sleep disorder characterized by chronic intermittent hypoxia (CIH), sleep fragmentation, and upper-airway collapse. Beyond respiratory issues, OSA significantly impacts the central nervous system, increasing the risk for mild cognitive impairment and dementia. This review synthesizes the dual nature of CIH-induced molecular cascades, describing pathways driving neurodegeneration, such as SUMOylation dysregulation, toll-like receptor signaling, and inflammasome overactivation (largely characterized in experimental and animal CIH models), and those activating endogenous neuroprotective adaptations. Physiological defense mechanisms, such as the upregulation of erythropoietin, shifts toward anaerobic glycolysis, and the activation of neurotrophic factors, may act to mitigate neuronal injury. Rather than acting as independent processes, these molecular responses form a dynamic balance between neuronal injury and endogenous neuroprotection. Here, we introduce the concept of 'neuroprotective reserve' as a novel, hypothesis-generating framework to describe this intrinsic buffering capacity against hypoxic stress. Understanding and clinically validating these pathways is critical for developing early diagnostic biomarkers and targeted adjunctive interventions that complement standard therapy to prevent irreversible neurocognitive decline.

Indexed as

cognitionneurodegenerationneuroprotectionobstructive sleep apnea

Identifiers

PMID42792228
PMCPMC13603200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.